RU2018119309A - Faecalibacterium prausnitzii и desulfovibrio piger для применения при лечении или предупреждении диабета и заболеваний кишечника - Google Patents
Faecalibacterium prausnitzii и desulfovibrio piger для применения при лечении или предупреждении диабета и заболеваний кишечника Download PDFInfo
- Publication number
- RU2018119309A RU2018119309A RU2018119309A RU2018119309A RU2018119309A RU 2018119309 A RU2018119309 A RU 2018119309A RU 2018119309 A RU2018119309 A RU 2018119309A RU 2018119309 A RU2018119309 A RU 2018119309A RU 2018119309 A RU2018119309 A RU 2018119309A
- Authority
- RU
- Russia
- Prior art keywords
- strain
- strains
- faecalibacterium prausnitzii
- use according
- paragraphs
- Prior art date
Links
- 241000605980 Faecalibacterium prausnitzii Species 0.000 title claims 13
- 241000604463 Desulfovibrio piger Species 0.000 title claims 9
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 208000028774 intestinal disease Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 4
- 206010010774 Constipation Diseases 0.000 claims 2
- 208000004104 gestational diabetes Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 241000239290 Araneae Species 0.000 claims 1
- 208000027244 Dysbiosis Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 claims 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 230000007140 dysbiosis Effects 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
Claims (22)
1. Штамм Faecalibacterium prausnitzii и штамм Desulfovibrio piger, который имеет одну или несколько характеристик из (i) продуцирования ацетата, (ii) потребления лактата и (iii) наличия способности быть акцептором электронов, для применения при лечении или предупреждении заболевания, ассоциированного с пониженными уровнями бутирата, или заболевания, ассоциированного с пониженным или низким числом бактерий Faecalibacterium prausnitzii.
2. Штаммы для применения по п.1, причем указанные штаммы вводят вместе в комбинации или последовательно или раздельно.
3. Штаммы для применения по п.1 или 2, причем указанный штамм имеет все характеристики (i)-(iii).
4. Штаммы для применения по любому из пп. 1-3, причем указанный штамм Faecalibacterium prausnitzii имеет (i) способность продуцировать бутират и, необязательно, одну или несколько характеристик из (ii) способности потреблять ацетат, (iii) способности продуцировать внеклеточные электроны и (iv) способности продуцировать лактат.
5. Штаммы для применения по п.4, причем указанный штамм Faecalibacterium prausnitzii имеет все характеристики (i)-(iv), и/или указанный штамм Desulfovibrio piger имеет все характеристики (i)-(iii).
6. Штаммы для применения по любому из пп. 1-5, причем указанный штамм Faecalibacterium prausnitzii содержит ген L-лактатдегидрогеназы.
7. Штаммы для применения по любому из пп. 1-6, причем, когда присутствуют оба штамма, продуцирование бутирата возрастает по сравнению с продуцированием одним штаммом Faecalibacterium prausnitzii.
8. Штаммы для применения по п.7, причем действие по возрастанию продуцирования бутирата является синергетическим действием.
9. Штаммы для применения по любому из пп. 1-8, причем указанный штамм Faecalibacterium prausnitzii представляет собой DSM 32186 или DSM 17677, и/или штамм Desulfovibrio piger представляет собой DSM 32187.
10. Штаммы для применения по любому из пп. 1-9, причем указанное применение приводит к повышенному росту и колонизации бактерий Faecalibacterium prausnitzii в желудочно-кишечном тракте.
11. Штаммы для применения по любому из пп. 1-10, причем указанное заболевание выбирают из группы, включающей дисбиоз, диабет типа 2, гестационный диабет, ожирение, подагру, паучит, хроническую болезнь почек, псориаз, немощь, воспалительное заболевание кишечника, синдром разраженного кишечника, абдоминальную боль, ассоциированную с синдромом разраженного кишечника, констипацию и заболевания, ассоциированные с констипацией.
12. Штаммы для применения по п.11, причем указанное заболевание представляет собой диабет типа 2 или гестационный диабет.
13. Штамм Desulfovibrio piger для применения при лечении или предупреждении заболевания, ассоциированного с пониженными уровнями бутирата, или заболевания, ассоциированного с пониженным или низким числом бактерий Faecalibacterium prausnitzii.
14. Штамм для применения по п.13, причем указанный штамм Desulfovibrio piger представляет собой DSM 32187, и/или указанное применение является применением по любому из пп. 10-12.
15. Композиция, включающая штамм Faecalibacterium prausnitzii и штамм Desulfovibrio piger, который имеет одну или несколько характеристик из (i) продуцирования ацетата, (ii) потребления лактата и (iii) наличия способности быть акцептором электронов.
16. Композиция по п.15, причем указанные штаммы являются штаммами по любому из пп. 3-9.
17. Набор, включающий
(i) штамм Faecalibacterium prausnitzii и
(ii) штамм Desulfovibrio piger, который имеет одну или несколько характеристик из (i) продуцирования ацетата, (ii) потребления лактата и (iii) наличия способности быть акцептором электронов.
18. Набор по п.17, причем указанные штаммы являются штаммами по любому из пп. 3-9.
19. Штамм Faecalibacterium prausnitzii DSM 32186.
20. Штамм Desulfovibrio piger DSM 32187.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1519088.7 | 2015-10-28 | ||
| GBGB1519088.7A GB201519088D0 (en) | 2015-10-28 | 2015-10-28 | The use of bacteria formulations |
| PCT/EP2016/076038 WO2017072278A1 (en) | 2015-10-28 | 2016-10-28 | Faecalibacterium prausnitzii and desulfovibrio piger for use in the treatment or prevention of diabetes and bowel diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2021113597A Division RU2797466C2 (ru) | 2015-10-28 | 2016-10-28 | Faecalibacterium prausnitzii и desulfovibrio piger для применения при лечении или предупреждении диабета и заболеваний кишечника |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018119309A true RU2018119309A (ru) | 2019-11-28 |
| RU2018119309A3 RU2018119309A3 (ru) | 2020-03-26 |
| RU2754367C2 RU2754367C2 (ru) | 2021-09-01 |
Family
ID=55130365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018119309A RU2754367C2 (ru) | 2015-10-28 | 2016-10-28 | Faecalibacterium prausnitzii и desulfovibrio piger для применения при лечении или предупреждении диабета и заболеваний кишечника |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11260082B2 (ru) |
| EP (1) | EP3368053A1 (ru) |
| JP (1) | JP7018396B2 (ru) |
| KR (2) | KR20180070698A (ru) |
| CN (2) | CN115778986A (ru) |
| AU (1) | AU2016344770B2 (ru) |
| BR (1) | BR112018008312B1 (ru) |
| CA (1) | CA3002603A1 (ru) |
| CL (1) | CL2018001133A1 (ru) |
| GB (1) | GB201519088D0 (ru) |
| IL (1) | IL258881B2 (ru) |
| MX (1) | MX392357B (ru) |
| RU (1) | RU2754367C2 (ru) |
| SG (1) | SG11201803062XA (ru) |
| UA (1) | UA124926C2 (ru) |
| WO (1) | WO2017072278A1 (ru) |
| ZA (1) | ZA201802585B (ru) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11959125B2 (en) * | 2016-09-15 | 2024-04-16 | Sun Genomics, Inc. | Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample |
| MY201921A (en) | 2017-06-16 | 2024-03-23 | Biofermin Pharmaceutical Co Ltd | Agent for preventing or treating fat-associated diseases and/or inflammation |
| AU2018313765A1 (en) * | 2017-08-07 | 2020-02-27 | Finch Therapeutics, Inc. | Compositions and methods for decolonizing antibotic-resistant bacteria in the gut |
| US11491192B2 (en) | 2018-01-09 | 2022-11-08 | The Cleveland Clinic Foundation | Treatment and prevention of pathogenic bacterial overgrowth using butyrate-producing bacteria |
| US20210393737A1 (en) * | 2018-09-25 | 2021-12-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of mam polypeptides for the treatment of obesity and obesity-related disorders |
| CN110878349A (zh) * | 2019-12-06 | 2020-03-13 | 深圳谱元科技有限公司 | 终末期肾病生物标志物及其应用 |
| EP3858363A1 (en) * | 2020-01-28 | 2021-08-04 | Institut national de recherche pour l'agriculture, l'alimentation et l'environnement | Composition for treating intestinal or pulmonary diseases |
| AU2021228209A1 (en) * | 2020-02-28 | 2022-08-11 | Stichting Amsterdam UMC | Intervention strategy for prevention or treatment of Diabetes mellitus, autoimmune disease, inflammatory disease or cardiovascular disease |
| NL2025020B1 (en) * | 2020-02-28 | 2021-10-14 | Acad Medisch Ct | Intervention strategy for prevention or treatment of autoimmune diseases |
| KR102169795B1 (ko) * | 2020-06-24 | 2020-10-27 | 주식회사 엔테로바이옴 | 신규한 피칼리박테리움 프로스니치 eb-fpdk9 균주 및 그의 용도 |
| KR102169794B1 (ko) * | 2020-06-24 | 2020-10-27 | 주식회사 엔테로바이옴 | 신규한 피칼리박테리움 프로스니치 균주 eb-fpdk11 및 그의 용도 |
| KR102185828B1 (ko) * | 2020-08-26 | 2020-12-03 | 주식회사 엔테로바이옴 | 피칼리박테리움 프로스니치 균주를 포함하는 아토피성 질환 예방 또는 치료용 약학적 조성물 |
| KR102245415B1 (ko) * | 2020-12-14 | 2021-04-29 | 주식회사 엔테로바이옴 | 피칼리박테리움 프로스니치 균주 배양 배지 조성물 |
| JP2024518270A (ja) * | 2021-05-06 | 2024-05-01 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | イノシトール、エリスリトール、又はソルビトールのうちの少なくとも１つを使用した、フィーカリバクテリウム・プラウスニッツィイの生育を増進するための組成物及び方法 |
| CN113201575A (zh) * | 2021-05-11 | 2021-08-03 | 西安医学院第一附属医院 | 基于普氏粪杆菌对动物肾脏炎症反应变化影响的研究方法 |
| CN113797232B (zh) * | 2021-10-28 | 2023-05-26 | 南昌大学 | 具有缓解胰岛素抵抗功能的组合物及其应用 |
| CN114304380A (zh) * | 2022-01-13 | 2022-04-12 | 合肥河川生物医药科技有限公司 | 普拉梭菌在猪鸡上的应用 |
| CN117384867B (zh) * | 2022-09-16 | 2024-06-07 | 北京普译生物科技有限公司 | 一种经修饰的Cas3移位酶及其应用 |
| CN117016672A (zh) * | 2023-08-29 | 2023-11-10 | 天晴干细胞股份有限公司 | 一种诱导2型糖尿病饲料及其在建立2型糖尿病动物模型中的应用 |
| CN118845848B (zh) * | 2024-07-01 | 2025-10-17 | 温州大学 | 普氏粪杆菌dsm 17677在制备防治猪流行性腹泻病毒感染产品中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ899700A0 (en) * | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| WO2006102350A1 (en) * | 2005-03-23 | 2006-09-28 | Washington University In St. Louis | The use of archaea to modulate the nutrient harvesting functions of the gastrointestinal microbiota |
| JP2007189947A (ja) * | 2006-01-19 | 2007-08-02 | Gifu Univ | 硫化水素産生菌抑制剤及び硫化水素産生菌抑制方法 |
| BR112014010660A2 (pt) * | 2011-11-04 | 2017-05-09 | Gen Mills Inc | métodos e composições para modular bactéria gastrointestinal |
| US9314494B2 (en) * | 2012-05-25 | 2016-04-19 | The United States Of America, As Represented By The Secretary Of Agriculture | Cranberry xyloglucan oligosaccharide composition |
| US8906668B2 (en) * | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| HK1214954A1 (zh) | 2013-03-05 | 2016-08-12 | 格罗宁根大学 | Faecalibacterium prausnitzii htf-f(dsm26943)在抑制炎症中的应用 |
| BR112015023124A2 (pt) * | 2013-03-14 | 2017-07-18 | Therabiome Llc | liberação de organismos probióticos e/ou agentes terapêuticos almejada para o trato gastrintestinal |
| CA2903053C (en) * | 2013-03-15 | 2023-01-17 | Amyris, Inc. | Use of phosphoketolase and phosphotransacetylase for production of acetyl-coenzyme a derived compounds |
| US20150246081A1 (en) * | 2014-03-03 | 2015-09-03 | Shayne Kenneth Morris | Probiotics with methods for growth and use separately and in combination |
| WO2019036176A1 (en) * | 2017-08-14 | 2019-02-21 | uBiome, Inc. | METHOD OF CHARACTERIZING THE MICROBIOMA ASSOCIATED WITH A DISEASE |
-
2015
- 2015-10-28 GB GBGB1519088.7A patent/GB201519088D0/en not_active Ceased
-
2016
- 2016-10-28 MX MX2018005261A patent/MX392357B/es unknown
- 2016-10-28 CN CN202310015135.4A patent/CN115778986A/zh active Pending
- 2016-10-28 BR BR112018008312-7A patent/BR112018008312B1/pt active IP Right Grant
- 2016-10-28 KR KR1020187015001A patent/KR20180070698A/ko not_active Ceased
- 2016-10-28 KR KR1020207037542A patent/KR102371868B1/ko active Active
- 2016-10-28 WO PCT/EP2016/076038 patent/WO2017072278A1/en not_active Ceased
- 2016-10-28 RU RU2018119309A patent/RU2754367C2/ru active
- 2016-10-28 UA UAA201805792A patent/UA124926C2/uk unknown
- 2016-10-28 JP JP2018541515A patent/JP7018396B2/ja active Active
- 2016-10-28 US US15/771,619 patent/US11260082B2/en active Active
- 2016-10-28 SG SG11201803062XA patent/SG11201803062XA/en unknown
- 2016-10-28 EP EP16788507.8A patent/EP3368053A1/en active Pending
- 2016-10-28 CN CN201680063240.3A patent/CN108367030B/zh active Active
- 2016-10-28 IL IL258881A patent/IL258881B2/en unknown
- 2016-10-28 AU AU2016344770A patent/AU2016344770B2/en active Active
- 2016-10-28 CA CA3002603A patent/CA3002603A1/en active Pending
-
2018
- 2018-04-18 ZA ZA2018/02585A patent/ZA201802585B/en unknown
- 2018-04-27 CL CL2018001133A patent/CL2018001133A1/es unknown
-
2022
- 2022-01-17 US US17/577,208 patent/US12318412B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018119309A (ru) | Faecalibacterium prausnitzii и desulfovibrio piger для применения при лечении или предупреждении диабета и заболеваний кишечника | |
| JP2018532779A5 (ru) | ||
| Sheng et al. | Synbiotic supplementation containing Bifidobacterium infantis and xylooligosaccharides alleviates dextran sulfate sodium-induced ulcerative colitis | |
| Anhê et al. | A polyphenol-rich cranberry extract reverses insulin resistance and hepatic steatosis independently of body weight loss | |
| JP2018199695A5 (ru) | ||
| Argenta et al. | Local application of probiotic bacteria prophylaxes against sepsis and death resulting from burn wound infection | |
| JP2016529309A5 (ru) | ||
| EA201101189A1 (ru) | Ингибитор sglt-2, предназначенный для лечения сахарного диабета типа 1, сахарного диабета типа 2, нарушенной толерантности к глюкозе или гипергликемии | |
| WO2011046616A3 (en) | Methods for modulating bacterial infection | |
| WO2011075539A3 (en) | Treatment of obesity or diabetes with bile acid sequestrants | |
| Miao et al. | Antibiotics can cause weight loss by impairing gut microbiota in mice and the potent benefits of lactobacilli | |
| WO2008105715A3 (en) | Use of lactobacillus plantarum for increasing bacterial diversity | |
| CN114040984B (zh) | 微生物的治疗性和预防性应用 | |
| Gullón et al. | Effects of hemicellulose-derived saccharides on behavior of Lactobacilli under simulated gastrointestinal conditions | |
| Duranti et al. | Bifidobacterium bifidum PRL2010 alleviates intestinal ischemia/reperfusion injury | |
| Yang et al. | Enhancing flora balance in the gastrointestinal tract of mice by lactic acid bacteria from Chinese sourdough and enzyme activities indicative of metabolism of protein, fat, and carbohydrate by the flora | |
| Hu et al. | L. johnsonii, L. plantarum, and L. rhamnosus alleviated Enterohaemorrhagic Escherichia coli-induced diarrhoea in mice by regulating gut microbiota | |
| Zhan et al. | Dietary 5-demethylnobiletin prevents antibiotic-associated dysbiosis of gut microbiota and damage to the colonic barrier | |
| JP2014113137A5 (ru) | ||
| Yang et al. | The Potential of clostridium butyricum to preserve gut health, and to mitigate non-AIDS comorbidities in people living with HIV | |
| Nogueira-Prieto et al. | A review of the capacity of xylooligosaccharides to modulate gut microbiota and promote health | |
| BRPI0924418A2 (pt) | composições e métodos para a prevenção e o tratamento de obesidade e síndrome metabólica relacionada à obesidade | |
| WO2008105540A1 (ja) | アレルギー疾患及び自己免疫疾患に有効な医薬及び食品 | |
| Yu et al. | Cross-talk between Pseudomonas aeruginosa and urinary tract infections | |
| Yang et al. | Clostridium difficile and gut health: Bacteria, the gut microbiome, and diet |